219 related articles for article (PubMed ID: 3860629)
1. Sequential high-dose cytosine arabinoside-asparaginase treatment in advanced childhood leukemia.
Wells RJ; Feusner J; Devney R; Woods WG; Provisor AJ; Cairo MS; Odom LF; Nachman J; Jones GR; Ettinger LJ
J Clin Oncol; 1985 Jul; 3(7):998-1004. PubMed ID: 3860629
[TBL] [Abstract][Full Text] [Related]
2. Sequential high-dose cytosine arabinoside and L-asparaginase in childhood leukemia in relapse.
Ettinger LJ; Biener R; Finklestein JZ; Kamalakar P; Jones GR; Avramis VI; Holcenberg JS
Semin Oncol; 1985 Jun; 12(2 Suppl 3):155-9. PubMed ID: 3859930
[No Abstract] [Full Text] [Related]
3. Treatment of poor risk acute leukemia with sequential high-dose ARA-C and asparaginase.
Capizzi RL; Poole M; Cooper MR; Richards F; Stuart JJ; Jackson DV; White DR; Spurr CL; Hopkins JO; Muss HB
Blood; 1984 Mar; 63(3):694-700. PubMed ID: 6696996
[TBL] [Abstract][Full Text] [Related]
4. [Induction of remission by sequential treatment with cytosine arabinoside (araC/high dose) and L-asparaginase].
Martín-Aragonés G; Sanz MA; Martínez JA; Rafecas FJ; Gomis F; Lorenzo I; Sanz G; Marty ML
Sangre (Barc); 1985; 30(1):15-21. PubMed ID: 3859023
[No Abstract] [Full Text] [Related]
5. Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide.
Tallman MS; Appelbaum FR; Amos D; Goldberg RS; Livingston RB; Mortimer J; Weiden PL; Thomas ED
J Clin Oncol; 1987 Jun; 5(6):918-26. PubMed ID: 3585446
[TBL] [Abstract][Full Text] [Related]
6. [High-dose cytosine arabinoside and L-asparaginase in the treatment of refractory or recurrent acute non-lymphoblastic leukemia].
Sanz MA; Borrego D; Martín-Aragonés G; Martínez JA; Lorenzo I; Sanz G; Sayas MJ; Jarque I; Pastor E; Rafecas J
Sangre (Barc); 1987; 32(4):476-81. PubMed ID: 3660187
[No Abstract] [Full Text] [Related]
7. Sequential high-dose ara-C and asparaginase in the therapy of previously treated and untreated patients with acute leukemia.
Capizzi RL; Powell BL; Cooper MR; Stuart JJ; Muss HB; Richards F; Jackson DV; White DR; Spurr CL; Zekan PJ
Semin Oncol; 1985 Jun; 12(2 Suppl 3):105-13. PubMed ID: 3892697
[No Abstract] [Full Text] [Related]
8. [Treatment of a case of childhood acute non-lymphocytic leukemia (ANLL) using high-dose cytosine arabinoside for intensification of early therapy].
Imashuku S; Nakajima T; Morimoto S; Hibi S; Todo S; Morioka Y; Sugimoto T
Gan To Kagaku Ryoho; 1987 Feb; 14(2):527-30. PubMed ID: 3813580
[TBL] [Abstract][Full Text] [Related]
9. Use of L-asparaginase and cytosine arabinoside for refractory acute lymphocytic leukemia with particular reference to T-cell leukemia.
Steuber CP; Levy GJ; Nix WL; Shepherd DA; Starling KA; Fernbach DJ
Med Pediatr Oncol; 1978; 5(1):33-8. PubMed ID: 311413
[TBL] [Abstract][Full Text] [Related]
10. Effective combination treatment of advanced acute lymphocytic leukemia with cytosine arabinoside (NSC-63878) and L-asparaginase (NSC-109229).
Ortega JA; Finklestein JZ; Ertel I; Hammond D; Karon M
Cancer Chemother Rep; 1972 Jun; 56(3):363-8. PubMed ID: 19051496
[TBL] [Abstract][Full Text] [Related]
11. High-dose cytosine arabinoside and L-asparaginase therapy for poor-risk adult acute nonlymphocytic leukemia. A retrospective study.
Evans C; Winkelstein A; Rosenfeld CS; Zeigler ZR; Shadduck RK
Cancer; 1990 Jun; 65(12):2624-30. PubMed ID: 2340464
[TBL] [Abstract][Full Text] [Related]
12. High-dose cytosine arabinoside and etoposide: an effective regimen without anthracyclines for refractory childhood acute non-lymphocytic leukemia.
Whitlock JA; Wells RJ; Hord JD; Janco RL; Greer JP; Gay JC; Edwards JR; McCurley TL; Lukens JN
Leukemia; 1997 Feb; 11(2):185-9. PubMed ID: 9009078
[TBL] [Abstract][Full Text] [Related]
13. [Etoposide (VP 16/NK 171) and cytosine arabinoside combination chemotherapy in refractory childhood leukemia].
Esumi N; Todo S; Arakawa S; Imashuku S
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):951-8. PubMed ID: 3963859
[TBL] [Abstract][Full Text] [Related]
14. High-dose cytosine arabinoside and L-asparaginase in refractory acute lymphoblastic leukemia: the Children's Cancer Group experience.
Harris RE; Sather HN; Feig SA
Med Pediatr Oncol; 1998 Apr; 30(4):233-9. PubMed ID: 9473758
[TBL] [Abstract][Full Text] [Related]
15. Peripheral neuropathy after high-dose cytosine arabinoside, daunorubicin, and asparaginase consolidation for acute nonlymphocytic leukemia.
Powell BL; Capizzi RL; Lyerly ES; Cooper MR
J Clin Oncol; 1986 Jan; 4(1):95-7. PubMed ID: 3001234
[TBL] [Abstract][Full Text] [Related]
16. Sequential high-dose cytosine arabinoside and asparaginase in refractory acute leukemia.
Capizzi RL; Cheng YC
Med Pediatr Oncol; 1982; 10 Suppl 1():221-8. PubMed ID: 6962320
[TBL] [Abstract][Full Text] [Related]
17. High-dose VP-16 with intermediate-dose cytosine arabinoside in the treatment of relapsed acute nonlymphocytic leukemia.
Chan HY; Meyers FJ; Lewis JP
Cancer Chemother Pharmacol; 1987; 20(3):265-6. PubMed ID: 3677301
[TBL] [Abstract][Full Text] [Related]
18. High-dose mercaptopurine followed by intermediate-dose cytarabine in relapsed acute leukemia.
Lockhart S; Plunkett W; Jeha S; Ramirez I; Zipf T; Cork A; Pinkel D
J Clin Oncol; 1994 Mar; 12(3):587-95. PubMed ID: 8120558
[TBL] [Abstract][Full Text] [Related]
19. Reversal of cytosine arabinoside (ara-C) resistance by the synergistic combination of 6-thioguanine plus ara-C plus PEG-asparaginase (TGAP) in human leukemia lines lacking or expressing p53 protein.
Fu CH; Martin-Aragon S; Weinberg KI; Ardi VC; Danenberg PV; Avramis VI
Cancer Chemother Pharmacol; 2001 Aug; 48(2):123-33. PubMed ID: 11561778
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group.
Avramis VI; Wiersma S; Krailo MD; Ramilo-Torno LV; Sharpe A; Liu-Mares W; Kowck R; Reaman GH; Sato JK
Clin Cancer Res; 1998 Jan; 4(1):45-52. PubMed ID: 9516951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
